MDG1.DE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 11:36):

Stats
Today's Volume	5 805.00
Average Volume	27 638.00
Market Cap	47.16M
EPS	€0 ( 2024-03-27 )
Next earnings date	( €0 ) 2024-04-25
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-2.91
ATR14	€0.0440 (2.32%)

Medigene AG Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Medigene AG Financials

Annual	2023
Revenue:	€6.03M
Gross Profit:	€2.98M (49.40 %)
EPS:	€-0.660

Q4	2023
Revenue:	€2.97M
Gross Profit:	€1.46M (49.06 %)
EPS:	€-0.370

Q2	2023
Revenue:	€1.55M
Gross Profit:	€1.11M (71.35 %)
EPS:	€-0.170

Q1	2023
Revenue:	€1.53M
Gross Profit:	€1.07M (69.91 %)
EPS:	€-0.140

Financial Reports:

No articles found.

Medigene AG

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.